-+ 0.00%
-+ 0.00%
-+ 0.00%
On the evening of November 17, Insilicon Smart announced on the Hong Kong Stock Exchange that just four months after the nomination of the pre-clinical drug candidate, Insilicon Smart has completed the first human administration of ISM9528. It is a non-opioid pain relief candidate discovered in Abu Dhabi with the potential to become the first of its kind. This exploratory trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral administration of ISM9528 in healthy adult volunteers. As the research progresses, Insili Intelligence may submit additional documents to relevant authorities and expand this exploratory test subject to regulatory approval.
Share
Listen to the news
On the evening of November 17, Insilicon Smart announced on the Hong Kong Stock Exchange that just four months after the nomination of the pre-clinical drug candidate, Insilicon Smart has completed the first human administration of ISM9528. It is a non-opioid pain relief candidate discovered in Abu Dhabi with the potential to become the first of its kind. This exploratory trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral administration of ISM9528 in healthy adult volunteers. As the research progresses, Insili Intelligence may submit additional documents to relevant authorities and expand this exploratory test subject to regulatory approval.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending